TD Cowen downgraded Surgery Partners to 'Hold' from 'Buy' and set a price target of $23.50, matching the acquisition price by HealthSpan Partners. This reflects the firm's adjustment to the announced merger terms, effectively removing upside potential for current shareholders.
TD Cowen downgraded Surgery Partners (SGRY) to 'Hold' from 'Buy' after the company announced its pending acquisition by HealthSpan Partners. The new price target of $23.50 aligns with the cash consideration offered in the merger agreement, which was disclosed on October 26, 2026. This move by TD Cowen signals that the firm believes the stock's valuation is now capped by the acquisition price, removing any significant upside potential for investors. For traders, this implies that SGRY's stock price is likely to trade near the $23.50 mark until the acquisition closes, with limited volatility unless the deal faces unexpected hurdles or a higher bid emerges. The short-term implication is a lack of growth catalysts for SGRY shareholders, while the long-term outlook will depend on HealthSpan Partners' strategy for the acquired entity.